CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Needham Initiates Immix Biopharma at Buy With $21 Price Target

Positive
AI Analysis

Summary

Needham initiated coverage of Immix Biopharma with a Buy rating and $21 price target.

Importance:3/10
Sentiment:
0.60
analyst_initiationbuy_ratingprice_target
Related Companies

Read the original article

Published by yahoo_finance on July 22, 2026 11:19 AM

Read Original